Today on MedNet21, we're going to discuss Chronic Kidney Disease.
The webcast will discuss the following:
- Prevalence of CKD
- Importance of recognizing CKD and it’s effect on mortality and morbidity
- CKD stages
- CKD work-up
- What to avoid in CKD
- New potassium binders
- Role of SGLT2-inhibitors in CKD
Dates and Times
End Date: 2/12/2024
ObjectivesAs a result of this educational activity, webcast participants will be able to: recognize the prevalence and importance of CKD; and realize the importance and effectiveness of SGLT2-inhibitors in halting the progression of CKD.
The Center for Continuing Medical Education (CCME) at The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians
The Center for Continuing Medical Education (CCME) at The Ohio State University designates this webcasts for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.